High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Abstract excerpt

Abstract Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore, we sought to understand the relationship between mutation and neoantigen landscape of MM patients and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Multiple Myeloma Research and Treatments
• Share to vaccines and immunoinformatics approaches